Innovative Development of Tumor-Infiltrating Lymphocyte Therapy
Juncell Therapeutics, a forward-thinking biotech company, is making remarkable strides in the field of cancer treatment through its advanced IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies. This clinical-stage enterprise is dedicated to improving the efficacy and accessibility of these therapies for solid tumors, offering hope to patients facing challenging cancer diagnoses.
Preclinical Study Presentation at Cancer Research Meeting
Recently, Juncell Therapeutics announced it would present compelling preclinical data at the prestigious American Association for Cancer Research (AACR) Annual Meeting. This data focuses on innovative pretreatment regimens that could enhance the immune response against tumors, demonstrating the company's commitment to pushing the boundaries of cancer therapy.
This significant preclinical study revealed that hydroxychloroquine (HCQ) has potential in improving tumor-killing effects. The findings indicate that HCQ can elevate the membrane MHC-I protein levels in tumor cells, contributing to an enhanced immune attack without detrimental effects on the proliferation capabilities of TILs. This exciting evidence supports the incorporation of HCQ pretreatment into the strategy for optimizing TIL therapy in upcoming clinical trials.
Details of the Presentation
During the AACR Annual Meeting, Juncell Therapeutics will feature the following details in their poster presentation:
Abstract Number: 5827
Abstract Title: Hydroxychloroquine increases the tumor killing efficiency via elevating the membrane MHC-I protein levels of tumor cells
Session Title: Immunomodulatory Agents and Interventions
Location: Poster Section 29
Poster Board Number: 3
Poster Presentation Time: 2:00 PM - 5:00 PM CST on April 29
Commitment to Accessible Cancer Treatments
Founded on the principle of making advanced cancer care accessible to all, Juncell Therapeutics is revolutionizing the landscape of tumor therapy. The company has developed its proprietary DeepTIL® cell expansion and NovaGMP® gene modification technology platforms. These innovations are specifically targeted at overcoming the challenges faced by traditional TIL therapies.
Juncell's clinical-stage TIL therapies have shown promising results across a diverse range of heavily pretreated advanced solid tumors. These include conditions such as lung cancer, triple-negative breast cancer, pancreatic cancer, high-grade glioma, and several others. Notably, seven patients with advanced cancer have achieved complete responses, with some experiencing tumor-free survival for more than three years.
About Juncell Therapeutics
Juncell Therapeutics is committed to producing high-quality, effective TIL therapies to combat solid tumors. The company continues to invest in research and innovation to expand treatment options that are not only robust and competent but also affordable and accessible. This relentless pursuit of excellence places Juncell Therapeutics at the forefront of cancer therapy development.
Frequently Asked Questions
What is Juncell Therapeutics focused on?
Juncell Therapeutics specializes in developing IL-2-independent TIL therapies aimed at treating solid tumors.
What is the significance of the preclinical study?
The study shows that hydroxychloroquine could enhance the efficacy of TIL therapies, potentially improving treatment outcomes.
When and where will the findings be presented?
The findings will be presented at the AACR Annual Meeting, specifically during a session dedicated to Immunomodulatory Agents.
What technologies does Juncell Therapeutics utilize?
Juncell uses innovative platforms including DeepTIL® for cell expansion and NovaGMP® for gene modification.
What are the results of Juncell's therapies so far?
The therapies have demonstrated promising safety and efficacy, with some patients achieving complete responses and extended tumor-free survival.
